NCT03472495View on ClinicalTrials.gov

Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

March 21, 2021

Study Completion Date

March 21, 2021

Conditions
Atrial Fibrillation and Flutter
Interventions
DRUG

Diltiazem Oral Product

Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is \<60 kg)

DRUG

Diltiazem Injectable Product

Diltiazem Continuous Infusion Titrated

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

All Listed Sponsors
lead

Virginia Commonwealth University

OTHER

NCT03472495 - Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial | Biotech Hunter | Biotech Hunter